Bipolar Disorder Clinical Trials in Austin

View 12 new treatments for Bipolar Disorder in Austin, TX, and other areas near me, such as Round Rock. Every day, Power helps hundreds of bipolar patients connect with leading medical research.
View 10 trials in Austin
Filter (10)

Multiple Medications for Bipolar Depression

Research Clinic, Austin + 1 more

This trial is testing four different medications to find the best treatment for adults with bipolar disorder type 1 who are currently depressed. The medications work by balancing brain chemicals that affect mood. The goal is to help patients recover from depression and stay well.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Cariprazine for Bipolar Disorder in Youth

AbbVie Clinic, Austin + 1 more

This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
ABBVIE INC.
Study Director

Lumateperone for Pediatric Bipolar Depression

Intra-Cellular Therapies Clinic, Austin + 1 more

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Cariprazine for Pediatric Schizophrenia

AbbVie Clinic, Austin + 1 more

This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 4 - 6 Weeks
ABBVIE INC.
Study Director

Lumateperone for Bipolar Mania

Intra-Cellular Therapies Clinic, Austin + 1 more

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

BHV-7000 for Bipolar Disorder

Biohaven Clinic, Austin + 1 more

The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
Recruiting
Phase 2 & 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

BHV-7000 for Bipolar Disorder

Biohaven Clinic, Austin + 1 more

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.
Waitlist

No Placebo Trial

Phase 2
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

VNS for Bipolar Depression

LivaNova Clinic, Austin + 2 more

This trial is testing whether VNS Therapy, which sends electrical impulses to the vagus nerve, can reduce depression symptoms in patients who haven't responded to other treatments. The study will observe the effects of VNS therapy over a year. Vagus nerve stimulation (VNS) is a recognized treatment for severe treatment-resistant depression and has shown promising results.Show More
Recruiting
N/A
Est. 3 - 12 Weeks
Charles Conway, MD
Principal Investigator

Alcohol Response for Bipolar Disorder

Research Clinic, Austin + 1 more

Alcohol use disorders (AUDs) affect up to 60% of individuals with bipolar disorder during their lifetime and is associated with worse illness outcomes, yet few studies have been performed to clarify the causes of this comorbidity. Understanding biological risk factors that associate with and predict the development of AUDs in bipolar disorder could inform interventions and prevention efforts to reduce the rate of this comorbidity and improve outcomes of both disorders. Identifying predictors of risk requires longitudinal studies in bipolar disorder aimed at capturing the mechanisms leading to the emergence of AUDs. Previous work in AUDs suggest that subjective responses to alcohol and stress-related mechanisms may contribute to the development of AUDs. In bipolar disorder, altered developmental trajectory of critical ventral prefrontal networks that modulate mood and reward processing may alter responses to alcohol and stressors; consequently, the disruption in typical neurodevelopment may be an underlying factor for the high rates of comorbidity. No longitudinal data exist investigating if this developmental hypothesis is correct. To address this gap, the investigators will use a multimodal neuroimaging approach, modeling structural and functional neural trajectories of corticolimbic networks over young adulthood, incorporating alcohol administration procedures, clinical phenotyping, and investigating effects of acute stress exposure and early life stress. Research aims are to identify biological risk factors-i.e., changes in subjective response to alcohol and associated neural trajectories-that are associated with the development of alcohol misuse and symptoms of AUDs over a two-year longitudinal period in young adults with bipolar disorder and typical developing young adults. Longitudinal data will be collected on 160 young adults (50% with bipolar disorder, 50% female; aged 21-26). This study is a natural extension of the PI's K01 award. How acute exposure to stress and childhood maltreatment affects subjective response to alcohol and risk for prospective alcohol misuse and symptoms of AUDs will be investigated. The investigators will test our hypothesis that developmental differences in bipolar disorder versus typical developing individuals disrupt corticolimbic networks during young adulthood, increase sensitivity to stress, and lead to changes in subjective response to alcohol and placebo response increasing risk for developing AUDs.Show More
Recruiting
N/A
Est. 4 - 6 Weeks
Elizabeth Lippard, PhD
Principal Investigator

Focused Ultrasound Neuromodulation for Affective Disorders

Research Clinic, Austin + 1 more

This trial is testing a new treatment using sound waves to target a part of the brain in people with emotional disorders like depression and anxiety. The treatment aims to change how this part of the brain works to improve symptoms. It is non-invasive and uses MRI to monitor changes in the brain.Show More
Waitlist

No Placebo Trial

N/A
Est. 3 - 6 Weeks
Gregory A Fonzo, Ph.D.
Principal Investigator
Page 1 of 1

Frequently Asked Questions

How much do bipolar clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do bipolar clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across bipolar trials in Austin, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for bipolar patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Austin is research being conducted for bipolar?

Community Clinical Research, Inc. in Austin is conducting clinical trials for bipolar disorder. Approximately 2 trials are ongoing as of the latest update.

What promising new drugs are being tested?

In Austin, research for bipolar disorder includes treatments like Atypical Antipsychotics and Vagus Nerve Stimulation. Specific interventions being studied are Cariprazine, BHV-7000, and Lumateperone.